LGP Little Green Pharma Ltd
Healthcare · Drug Manufacturers - Specialty & Generic
· website
$0.07
52wk 0.06 – 0.14
Overall
61.2
Value
96.6
Growth
57.3
Health
70.2
Quality
56.4
Momentum
12.0
Dividend
—
Price
About Little Green Pharma Ltd
Little Green Pharma Ltd produces and sells cannabis-based medicinal products across Australia and Europe. The company also provides infrastructure to support plant genetics programs and the development of its flower portfolio. It sells its products through a network of wholesalers, pharmacies, clinics, and GPs (general practitioners). The company was founded in 2016 and is based in Wembley, Australia.
Price analytics
Returns
| 1 day | 4.5% |
| 1 week | -2.8% |
| 1 month | 9.4% |
| 3 months | 2.9% |
| 6 months | -27.8% |
| 1 year | -46.2% |
| 3 years | -57.6% |
Risk
| Volatility (1y ann.) | 58.6% |
| Beta vs ASX 200 | 0.55 |
| Sharpe (1y) | -0.83 |
| VaR 95% (1-day) | -4.8% |
| Max drawdown (1y) | -56.4% |
| Off 1-year high | -50.0% |
Technicals
| RSI(14) | 48 |
| vs 50DMA | -1.1% |
| vs 200DMA | -24.5% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
96.6
Trailing P/E
—
Forward P/E
93
PEG ratio
—
EV / EBITDA
—
Price / Book
100
Price / Sales
100
Growth
57.3
Revenue growth (1y)
72
Revenue CAGR (3y)
100
EPS growth (1y)
0
EPS CAGR (3y)
—
Financial Health
70.2
Net debt / EBITDA
70
Interest coverage (EBIT/interest)
41
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)
56.4
Return on equity
70
Return on assets
83
Operating margin
44
Net margin
28
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
12.0
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
44
Position in 52-week range
12
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$57.96M
P/E (trailing)
—
P/E (forward)
10.00
EPS (trailing)
0.00
Dividend yield
—
Payout ratio
0.0%
Beta
0.32
EV / EBITDA
—
Price / Book
0.37
ROE
14.0%
Operating margin
11.0%
Net margin
4.2%
Total cash
—
Total debt
—
Current ratio
3.81
Debt / Equity
—
Free cash flow
$2.73M
Avg volume
216,749
Latest annual results
(FY ending 31 Mar 2026)
- Revenue$42.42M
- Gross profit$30.14M
- Operating income$2.12M
- Net income-$1.41M
- Diluted EPS-0.00
- Free cash flow-$960.00K
- Net debt$3.27M